Showing results (501-510 of 542) with videos related to
Sort By:
Pageof 55
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trialMarc Bourlière, Pascaline Rabiega, Nathalie Ganne-Carrie, et al.Clinics and Research in Hepatology and Gastroenterology|June 30, 2020
Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohortAnais Vallet-Pichard, Jean-Michel Correas, Celine Dorival, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 1, 2011
Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian WorkshopGiampiero Carosi, Mario Rizzetto, Alfredo Alberti, et al.JHEP Reports : Innovation in Hepatology|September 18, 2024
HBV-related HCC development in mice is STAT3 dependent and indicates an oncogenic effect of HBxMarc Ringelhan, Svenja Schuehle, Maarten van de Klundert, et al.Viruses|February 28, 2020
A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in VitroRomina Salpini, Lorenzo Piermatteo, Arianna Battisti, et al.Liver International : Official Journal of the International Association for the Study of the Liver|June 11, 2026
Liver Transplantation for HBV-Related Disease in France: NUC Type Before LT Is Associated With Patient SurvivalIsaure Bienvenue, Olivier Roux, Audrey Coilly, et al.The Lancet. Infectious Diseases|March 17, 2015
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)Marc Bourlière, Jean-Pierre Bronowicki, Victor de Ledinghen, et al.JHEP Reports : Innovation in Hepatology|July 24, 2023
Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort studyMilan J Sonneveld, Shao-Ming Chiu, Jun Yong Park, et al.Journal of Hepatology|January 29, 2022
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levelsMilan J Sonneveld, Shao-Ming Chiu, Jun Yong Park, et al.Journal of Hepatology|May 21, 2014
Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemiaMathilde Di Filippo, Philippe Moulin, Pascal Roy, et al.Pageof 55